Day Two Afternoon Session

Wednesday, 6 April 2016 at 13:59

Add to Calendar ▼2016-04-06 09:00:002016-04-06 10:00:00Europe/LondonBringing Biologically Relevant Cells to Life - iPSC Technology in Lead Discovery and Safety AssessmentStem Cells in Drug Discovery 2016 in Cambridge, UKCambridge, UKSELECTBIOenquiries@selectbiosciences.com

Bringing Biologically Relevant Cells to Life - iPSC Technology in Lead Discovery and Safety Assessment

Wednesday, 6 April 2016 at 09:00

Add to Calendar ▼2016-04-06 09:00:002016-04-06 10:00:00Europe/LondonBringing Biologically Relevant Cells to Life - iPSC Technology in Lead Discovery and Safety AssessmentStem Cells in Drug Discovery 2016 in Cambridge, UKCambridge, UKSELECTBIOenquiries@selectbiosciences.com

AstraZeneca present data, showing large scale generation of functional pancreatic beta-cells, at a scale commensurate with drug-discovery activities. Furthermore, data is presented demonstrating the power of combining precise genome editing with iPSC technology in target validation.

Alexander Kvist, Associate Principle Scientist, AstraZeneca

Alexander Kvist

Dr Kvist is an Associate Principle Scientist in the Stem and Primary Cell group within Discovery Sciences at AstraZeneca in Gothenburg, Sweden. The focus of his work is the application of iPSC technology to derive and apply complex cellular models to drive target identification and validation as well as hit and lead generation and safety assesment. He was recuited by AstraZeneca in 2008, initially leading a team focused on generation and validation of affinity reagents for all AstraZeneca disease areas and stages of drug discovery. He subsequently moved into the stem cell area where he has worked on the generation and application of cellular models for drug discovery in the areas of cardiac regeneration, diabetic health and hepatotoxicity prediction, generating assays driving drug-project progression. Dr Kvist recieved his Bsc (Hons) from Univerisity of Manchester and a PhD from Lund University where he also spent some time as a Post-Doc.